Boston, MA, United States
Boston, MA, United States

Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital . Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973. Wikipedia.


Time filter

Source Type

Patent
University of Virginia and Beth Israel Deaconess Medical Center | Date: 2016-08-03

Methods, systems, and computer-readable media for rapid 3D dynamic arterial spin labeling with a sparse model-based image reconstruction are disclosed. In one embodiment, a method includes acquiring magnetic resonance data associated with an area of interest of a subject. The magnetic resonance data includes associated with arterial spin labeling (ASL) of the area of interest. The method also includes performing image reconstruction on the acquired resonance data. The image reconstruction includes compressed sensing enforcing a model-based sparsity constraint, where the model-based sparsity constraint is based on an ASL signal prototype dictionary.


The present invention features methods of extracting amylase trypsin inhibitors (ATIs) from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff.


Patent
Beth Israel Deaconess Medical Center and The General Hospital Corporation | Date: 2016-11-15

Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of 1-antitrypsin.


Patent
Boston University and Beth Israel Deaconess Medical Center | Date: 2016-07-29

Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells.


Patent
Beth Israel Deaconess Medical Center | Date: 2015-06-03

Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.


Patent
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Massachusetts General Hospital | Date: 2015-12-11

Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.


Ahmed M.,Beth Israel Deaconess Medical Center
Radiology | Year: 2014

Image-guided tumor ablation has become a well-established hallmark of local cancer therapy. The breadth of options available in this growing field increases the need for standardization of terminology and reporting criteria to facilitate effective communication of ideas and appropriate comparison among treatments that use different technologies, such as chemical (eg, ethanol or acetic acid) ablation, thermal therapies (eg, radiofrequency, laser, microwave, focused ultrasound, and cryoablation) and newer ablative modalities such as irreversible electroporation. This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies. An appropriate vehicle is proposed for reporting the various aspects of image-guided ablation therapy including classification of therapies, procedure terms, descriptors of imaging guidance, and terminology for imaging and pathologic findings. Methods are addressed for standardizing reporting of technique, follow-up, complications, and clinical results. As noted in the original document from 2003, adherence to the recommendations will improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes. © RSNA, 2014.


Stern R.S.,Beth Israel Deaconess Medical Center
New England Journal of Medicine | Year: 2012

A 50-year-old woman with bipolar depression presents with a widespread pruritic rash of 1 day's duration. She is afebrile and otherwise well. She has a history of childhood eczema and is allergic to sulfonamide antibiotics. Her medications include thyroxine daily, naproxen intermittently, and lamotrigine, which she began taking 3 weeks earlier. How should this case be evaluated and treated? Copyright © 2012 Massachusetts Medical Society.


Tsokos G.C.,Beth Israel Deaconess Medical Center
New England Journal of Medicine | Year: 2011

SLE is an autoimmune disease that predominantly affects women and typically has manifestations in multiple organs. Immune-system aberrations, as well as heritable, hormonal, and environmental factors, contribute to the expression of organ damage. Immune complexes, autoantibodies, autoreactive lymphocytes, dendritic cells, and local factors are all involved in clinical manifestations of SLE. Biologic therapies and small-molecule drugs that can correct the aberrant immune-cell function are being developed in the hope that they will be more effective and less toxic than current treatments. Copyright © 2011 Massachusetts Medical Society.


Medici D.,Beth Israel Deaconess Medical Center
Nature medicine | Year: 2010

Mesenchymal stem cells can give rise to several cell types, but varying results depending on isolation methods and tissue source have led to controversies about their usefulness in clinical medicine. Here we show that vascular endothelial cells can transform into multipotent stem-like cells by an activin-like kinase-2 (ALK2) receptor-dependent mechanism. In lesions from individuals with fibrodysplasia ossificans progressiva (FOP), a disease in which heterotopic ossification occurs as a result of activating ALK2 mutations, or from transgenic mice expressing constitutively active ALK2, chondrocytes and osteoblasts expressed endothelial markers. Lineage tracing of heterotopic ossification in mice using a Tie2-Cre construct also suggested an endothelial origin of these cell types. Expression of constitutively active ALK2 in endothelial cells caused endothelial-to-mesenchymal transition and acquisition of a stem cell-like phenotype. Similar results were obtained by treatment of untransfected endothelial cells with the ligands transforming growth factor-β2 (TGF-β2) or bone morphogenetic protein-4 (BMP4) in an ALK2-dependent manner. These stem-like cells could be triggered to differentiate into osteoblasts, chondrocytes or adipocytes. We suggest that conversion of endothelial cells to stem-like cells may provide a new approach to tissue engineering.

Loading Beth Israel Deaconess Medical Center collaborators
Loading Beth Israel Deaconess Medical Center collaborators